No Data
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel, June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Compugen Earns Milestone From AstraZeneca Trial
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen Ltd. (NASDAQ:CGEN) Just Reported Earnings, And Analysts Cut Their Target Price
Compugen Ltd. (NASDAQ:CGEN) investors will be delighted, with the company turning in some strong numbers with its latest results. The results were impressive, with revenues of US$2.6m exceeding a
Compugen's Strategic Shift to PROC Program Merits a Buy Rating